Health Canada Approves the Use of RINVOQ® for the Treat

Authorization is based on the results from three Phase 3 multicenter, randomized, double-blind, placebo-controlled registrational clinical trials evaluating the efficacy and safety or RINVOQ in monotherapy or in combination with topical corticosteroids. 1 RINVOQ demonstrated improvements in skin clearance and itch reduction compared to placebo. Milestone marks the third Health Canada-approved indication for RINVOQ ...

Related Keywords

Canada , Waterloo , Ontario , Canadians , Canadian , Kim Alexander Papp , Amanda Cresswell Melville , Tracey Ramsay , Linkedin , Abbvie Company , Twitter , Eczema Society Of Canada , Abbvie Corporation , Canadian Dermatology Association , Probity Medical Research , Allergan , K Papp Clinical Research , Health Canada , Health Canada Approved , Clinical Research , Eczema Area , Severity Index , Global Assessment , Atopic Dermatitis , Executive Director , Vice President , General Manager , Allergan Aesthetics ,